2015
The Lifetime Medical Cost Savings From Preventing HIV in the United States
Schackman BR, Fleishman JA, Su AE, Berkowitz BK, Moore RD, Walensky RP, Becker JE, Voss C, Paltiel AD, Weinstein MC, Freedberg KA, Gebo KA, Losina E. The Lifetime Medical Cost Savings From Preventing HIV in the United States. Medical Care 2015, 53: 293-301. PMID: 25710311, PMCID: PMC4359630, DOI: 10.1097/mlr.0000000000000308.Peer-Reviewed Original ResearchConceptsHIV infectionLifetime medical costsMedical costsUS health system perspectiveAntiretroviral treatment statusHIV disease treatmentHIV Research NetworkTransmission risk groupsCD4 cell countHigh-risk individualsHealth system perspectiveHIV prevention interventionsMedical cost savingsMedical Expenditure Panel SurveyLifetime cost estimatesRace/ethnicityPreexposure prophylaxisHIV diseaseHIV preventionRisk groupsPrevention interventionsAge 35High riskSecondary infectionTreatment status
2007
The Effect of Antiretroviral Therapy on Secondary Transmission of HIV among Men Who Have Sex with Men
McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, Paltiel AD, Freedberg KA, Seage GR. The Effect of Antiretroviral Therapy on Secondary Transmission of HIV among Men Who Have Sex with Men. Clinical Infectious Diseases 2007, 44: 1115-1122. PMID: 17366461, PMCID: PMC2365722, DOI: 10.1086/512816.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyCohort of individualsHuman immunodeficiency virus RNA loadEffect of ARTImpact of ARTFurther HIV transmissionUnprotected insertive anal intercourseHIV RNA levelsVirus RNA loadCohort of menSecondary transmissionYears of infectionInsertive anal intercourseRisk reduction interventionsHIV diseaseHIV infectionUntreated cohortHIV transmissionRNA loadVirologic courseSecondary casesAnal intercourseSecondary infectionHIVEffective HIV